Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Outsourcing

Merck boosts viral vectors in California

by Rick Mullin
October 23, 2021 | A version of this story appeared in Volume 99, Issue 39

 

A photo of people in clean-room gear working in a plant.
Credit: Merck KGaA
At work in Merck's new viral vector facility

Merck KGaA has opened a second viral vector manufacturing facility in Carlsbad, California. The $116 million, 13,000 m2 plant will more than double the site’s commercial-scale capacity. With the new facility, Merck will operate 30 clean rooms and reactors with production capacity of up to 1,000 L. Other large pharmaceutical services companies, including Thermo Fisher Scientific and Charles River Laboratories, are also ramping up viral vector services.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.